Business Context and Reporting Period
Company: OraSure Technologies, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 2011
Business Overview: The company develops, manufactures, and markets oral fluid diagnostic products, specimen collection devices, and medical devices for cryosurgery. Key products include the OraQuick HIV and HCV tests, Intercept drug testing systems, and Histofreezer cryosurgical systems. Sales are conducted in the United States and internationally to laboratories, hospitals, clinics, and distributors.
Key Financial Metrics
| Metric | Q1 2011 | Q1 2010 |
|---|---|---|
| Total Revenues | $17.41 million | $17.95 million |
| Gross Profit | $11.27 million | $11.40 million |
| Gross Margin | 65% | 64% |
| Operating Loss | $(2.55) million | $(2.18) million |
| Net Loss | $(2.60) million | $(2.20) million |
| Loss Per Share (Basic/Diluted) | $(0.06) | $(0.05) |
| Cash Used in Operating Activities | $(2.05) million | $(5.00) million |
| Cash and Cash Equivalents (End of Period) | $70.54 million | $69.37 million |
| Short-term Investments | $1.90 million | $1.90 million |
| Current Portion of Long-term Debt | $7.67 million | $7.79 million |
| Working Capital | $76.03 million | $77.81 million |
Material Changes vs. Prior Period
- Revenue Decline: Total revenues decreased 3% to $17.41 million. While product revenues increased 3% (driven by infectious disease and substance abuse testing), licensing and product development revenues dropped 73% to $0.36 million. This decline was primarily due to the absence of a $1.0 million milestone payment from Merck received in Q1 2010 for the OraQuick HCV test.
- Increased Operating Loss: Net loss widened to $2.60 million from $2.20 million. This was driven by a 42% increase in Research and Development (R&D) expenses to $4.42 million, largely due to clinical trial costs for the OraQuick HIV OTC test.
- Improved Cash Flow: Cash used in operating activities improved significantly, decreasing from $5.00 million in Q1 2010 to $2.05 million in Q1 2011, despite the net loss.
- Market Performance:
- Infectious Disease: Revenues increased 5% to $10.0 million, with international OraQuick HIV sales up 115%.
- Substance Abuse: Revenues increased 13% to $3.1 million, driven by domestic Intercept system sales.
- Cryosurgical Systems: Revenues decreased 9% to $2.7 million, primarily due to a 32% drop in OTC sales in Latin America (Genomma distributor) following regulatory advertising limitations in Mexico.
Guidance, Outlook, and Risks
- Product Pipeline & Regulatory:
- OraQuick HCV: FDA approval for oral fluid use is delayed pending additional testing. A CLIA waiver application for venous/fingerstick blood use was submitted in March 2011 and remains pending.
- OraQuick HIV OTC: Final phase clinical testing is underway with over 2,500 patients enrolled; completion is expected in Q3 2011.
- Substance Abuse: FDA issued 510(k) clearances for high-throughput assays for PCP, opiates, cocaine, and methamphetamines. Commercialization with Roche Diagnostics is expected in Q3 2011.
- QuickFlu: Launched the OraSure QuickFlu Rapid Flu A+B test in Q1 2011.
- Liquidity & Debt: The company holds $72.4 million in cash and short-term investments, deemed sufficient for operations for at least the next 12 months. A $10 million credit facility with Comerica Bank expires in June 2011 with no available borrowings currently; the company is evaluating refinancing options.
- Risks:
- Competition: Intense competition in HIV testing (lower-priced blood tests) and substance abuse testing (automated oral fluid systems from competitors).
- Regulatory Dependence: Reliance on sole-source suppliers for critical components and the need for FDA approvals/CLIA waivers to expand market access.
- Economic Conditions: Ongoing economic downturn may reduce public funding for customers and delay sales cycles.
Investor Verification Checklist
- Debt Refinancing: Verify the status of the $10 million Comerica credit facility expiring in June 2011 and the company's plan to refinance or replace it.
- Regulatory Milestones: Monitor the FDA's decision on the OraQuick HCV CLIA waiver and the timeline for the OraQuick HIV OTC clinical trial completion.
- Distributor Relationships: Assess the impact of the loss of Genomma sales in Latin America and the renewal status of the Reckitt Benckiser distribution contract (extended through June 2011).
- R&D Spend: Track the trajectory of R&D expenses, which rose 42% YoY, to ensure they align with product launch timelines and do not erode cash reserves faster than anticipated.
- Revenue Mix: Confirm the sustainability of product revenue growth given the one-time nature of the licensing revenue decline in the prior year.